Initiating biennial breast screening for Black women at age 40 years rather than the US standard of 50 years could substantially reduce Black–White breast cancer mortality disparities without increasing harms, modelling data suggest.
Using thoracic ultrasonography to guide pleurodesis leads to shorter hospital stays, with similar success rates, compared with standard care in people with malignant pleural effusion, SIMPLE study findings indicate.
Toxicity Index data plus patient-reported outcomes may provide greater insights into reasons for early discontinuation of endocrine therapy than maximum-grade adverse event data alone, US study findings indicate.
Premenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer derive a significant progression-free survival benefit from the addition of everolimus to first-line letrozole, shows the MIRACLE trial.
Previously treated patients with HER2-positive metastatic breast cancer derive a significant progression-free survival benefit from the novel HER2-targeted antibody–drug conjugate trastuzumab duocarmazine relative to standard treatment, shows the TULIP trial.
The final overall survival findings from the MONALEESA-2 trial confirm the long-term benefits of combining ribociclib with first-line letrozole for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer.
Extending adjuvant aromatase inhibitor therapy with letrozole to 5 years improves survival among women with hormone receptor-positive breast cancer who have already received 2 to 3 years of tamoxifen, shows the phase 3 GIM4 trial.
Previously treated patients with HER2-positive metastatic breast cancer derive a significant progression-free survival benefit from trastuzumab deruxtecan relative to trastuzumab emtansine, find the DESTINY-Breast03 investigators.
Adding carboplatin to neoadjuvant paclitaxel is sufficient to boost the outcomes of patients with triple-negative breast cancer, with no further improvement from the addition of veliparib to the dual regimen, confirms a follow-up analysis of the BrighTNess trial.